Healthcare provider profile · identity verified

Chisara Adonai, MD

Family Practice · YULEE, FL · NPI 1609873868

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	406	141
Amlodipine Besylate	Amlodipine Besylate	243	88
Lisinopril	Lisinopril	177	61
Losartan Potassium	Losartan Potassium	168	57
Levothyroxine Sodium	Levothyroxine Sodium	144	51
Prednisone	Prednisone	138	76
Gabapentin	Gabapentin	133	52
Rosuvastatin Calcium	Rosuvastatin Calcium	127	49
Omeprazole	Omeprazole	120	39
Pantoprazole Sodium	Pantoprazole Sodium	115	39
Azithromycin	Azithromycin	108	66
Albuterol Sulfate Hfa	Albuterol Sulfate	88	40
Furosemide	Furosemide	82	33
Alendronate Sodium	Alendronate Sodium	81	32
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	79	31
Metformin Hcl	Metformin Hcl	76	32
Fluticasone Propionate	Fluticasone Propionate	75	35
Trazodone Hcl	Trazodone Hcl	73	30
Tamsulosin Hcl	Tamsulosin Hcl	72	31
Jardiance	Empagliflozin	70	25
Metoprolol Tartrate	Metoprolol Tartrate	70	17
Carvedilol	Carvedilol	68	26
Ezetimibe	Ezetimibe	66	21
Montelukast Sodium	Montelukast Sodium	65	26
Ozempic	Semaglutide	65	15
Metoprolol Succinate	Metoprolol Succinate	61	20
Hydrochlorothiazide	Hydrochlorothiazide	59	28
Zolpidem Tartrate	Zolpidem Tartrate	56	11
Sertraline Hcl	Sertraline Hcl	51	18
Clonazepam	Clonazepam	50	suppressed
Eliquis	Apixaban	48	17
Paroxetine Hcl	Paroxetine Hcl	47	13
Mounjaro	Tirzepatide	43	suppressed
Allopurinol	Allopurinol	42	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	42	27
Simvastatin	Simvastatin	42	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	15
Duloxetine Hcl	Duloxetine Hcl	39	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	14
Famotidine	Famotidine	33	17
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	31	28
Glipizide Er	Glipizide	31	12
Atenolol	Atenolol	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	13
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	30	22
Escitalopram Oxalate	Escitalopram Oxalate	29	13
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Rybelsus	Semaglutide	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Spironolactone	Spironolactone	25	13
Dropsafe Prep Pads	Alcohol Antiseptic Pads	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Diazepam	Diazepam	23	suppressed
Potassium Chloride	Potassium Chloride	23	suppressed
Ibuprofen	Ibuprofen	22	12
Methocarbamol	Methocarbamol	22	suppressed
Topiramate	Topiramate	22	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	21	suppressed
Glipizide	Glipizide	21	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Naloxone Hcl	Naloxone Hcl	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	20	suppressed
Celecoxib	Celecoxib	20	11
Meloxicam	Meloxicam	20	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	suppressed
Cephalexin	Cephalexin	19	17
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	16
Glimepiride	Glimepiride	18	suppressed
Sildenafil Citrate	Sildenafil Citrate	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Finasteride	Finasteride	17	suppressed
Latanoprost	Latanoprost	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Linzess	Linaclotide	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Asa-Butalb-Caffeine-Codeine	Codeine/Butalbital/Asa/Caffein	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Promethazine Hcl	Promethazine Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Nifedipine Er	Nifedipine	12	11
Ondansetron Odt	Ondansetron	12	suppressed
Valsartan	Valsartan	12	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error